In the intricate dance of our body’s defences against harmful invaders, certain immune system proteins play pivotal roles.
New research from the Bridge Institute at the USC Michelson Center for Convergent Bioscience, in collaboration with international teams from India, Australia and Switzerland, has shed light on these proteins.
The work potentially paves the way for innovative treatments for a range of diseases, including severe cases of COVID-19, rheumatoid arthritis, neurodegenerative diseases and cancer.
Central to our immune response is the complement cascade, a series of events activated when potential threats are detected.
This process produces protein messengers, C3a and C5a, which in turn activate specific receptors on cells, setting off a cascade of internal signals.
The precise mechanisms of these receptors, especially the elusive C5aR1, have remained a mystery.
Using the advanced technique of cryo-electron microscopy (cryo-EM), the researchers captured detailed images of these receptors in action.
These images unveil how the receptors interact with molecules, change shape upon activation and transmit signals within the cell.
The study’s lead author, Cornelius Gati, assistant professor of biological sciences, chemistry, and quantitative and computational biology at the USC Dornsife College of Letters, Arts and Sciences, remarked on the findings, noting, “This research offers significant and comprehensive insights into a crucial receptor family within the immune system.”
The study’s revelations suggest potential avenues for the development of drugs targeting these receptors to treat various diseases, added Gati.
As the global community continues to grapple with diseases that impact millions, understanding the nuances of our immune system becomes ever more critical.
This research, published in the journal Cell on October 17, contributes to that understanding, providing a foundation for future studies aiming to harness the power of our body’s natural defences.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.